Inventiva Publishes Presentation on Lanifibranor's Antifibrotic Effects in Preclinical Models

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Inventiva published a medical research presentation showing investigational lanifibranor reduced liver fibrosis across preclinical models. * Balanced pan-PPAR activation improved liver-cell metabolism, dampened macrophage-driven inflammation and supported function across other hepatic cell populations. * The findings support further development of lanifibranor as an antifibrotic therapy for metabolic dysfunction-associated steatohepatitis (MASH). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inventiva SA published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.